Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gains from Investment Securities: 2021-2024

Historic Gains from Investment Securities for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $7.7 million.

  • Amylyx Pharmaceuticals' Gains from Investment Securities rose 430.06% to $5.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $7.5 million, marking a year-over-year increase of 2.27%. This contributed to the annual value of $7.7 million for FY2024, which is 21.32% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Gains from Investment Securities of $7.7 million as of FY2024, which was down 21.32% from $9.8 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Gains from Investment Securities ranged from a high of $9.8 million in FY2023 and a low of $5.3 million during FY2021.
  • For the 3-year period, Amylyx Pharmaceuticals' Gains from Investment Securities averaged around $8.7 million, with its median value being $8.5 million (2022).
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Gains from Investment Securities surged by 58.85% in 2022 and then dropped by 21.32% in 2024.
  • Amylyx Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $5.3 million in 2021, then soared by 58.85% to $8.5 million in 2022, then climbed by 15.83% to $9.8 million in 2023, then declined by 21.32% to $7.7 million in 2024.